WASHINGTON DC – A narrow federal window is opening that could reshape the future of the U.S. cannabis industry—and Michigan companies may have just weeks to decide whether to take part.
The Drug Enforcement Administration has launched a new registration process for medical marijuana businesses, creating what some industry attorneys describe as a rare opportunity to secure early positioning in what could eventually become a national—and even global—cannabis market.
The catch: companies have roughly 60 days to apply.
Miss that window, and they may miss far more than a filing deadline.
A Calculated Bet With High Stakes
The new registration pathway is tied to the federal government’s ongoing review of marijuana under the Controlled Substances Act, where cannabis remains classified as a Schedule I drug.
While the process does not legalize marijuana at the federal level, it offers something many operators have never had: a potential foothold inside a federally recognized framework.
That foothold comes at a price—and with no guarantees.
Legal analysts describe the move as a calculated bet: spend thousands of dollars now for a chance at outsized long-term gains.
Estimates suggest the cost of applying could range from $10,000 to $15,000 when legal, compliance, and administrative expenses are included. The potential payoff, if federal barriers fall, could be significantly higher.
First Movers Could Shape the Market
The biggest incentive for companies to act quickly is the possibility of early approval—and with it, early influence.
Some legal experts believe applicants who file immediately could receive federal registration within months, positioning them ahead of competitors in what could eventually become an interstate cannabis market.
That matters because federal registration could open doors that are currently closed, including broader distribution opportunities and participation in federally compliant supply chains.
In short, early applicants may not just enter the next phase of the industry—they may help define it.
“The big change applicants will want to see in the future is a shift from medical or research-based activity to full commercial sales,” said Mohamed A. Ghaith, managing partner at Oak Law. “Likely the only way to be part of that conversation is if you already have a medical registration.”
His comments reflect a growing belief that this process is not just about access—but about influence—giving early participants a seat at the table as federal regulators shape what comes next.
Michigan Operators Face Familiar Uncertainty
For many in Michigan’s cannabis sector, the situation feels less like a breakthrough—and more like déjà vu.
“This is consistent with how the cannabis industry has developed from the beginning,” said Josh Covert, CEO of Meds Café. “Operators are constantly being forced to make major business decisions before the rules are clear, before regulators have answered the practical questions, and before anyone really knows what the long-term consequences will be.”
That uncertainty, he said, is baked into the business.
“That is the reality of being in cannabis. Businesses are expected to invest money, sign leases, hire people, build compliance systems, and make strategic decisions while the legal framework is still being built around them,” Covert said.
The federal registration window, he added, is simply the latest—and perhaps most consequential—version of that dynamic.
“This feels like another version of that same problem,” he said. “There may be a real opportunity here, but companies are being asked to decide quickly, with incomplete information, in an industry where one regulatory decision can affect taxes, licensing, banking, operations, and future market position.”
Risks Remain Despite Opportunity
Even for companies willing to take the leap, the risks are real—and not fully understood.
Marijuana remains federally illegal, and the registration process could face legal or political challenges. There is no guarantee that businesses applying now will ultimately receive approval—or that the framework itself won’t shift before it fully takes hold.
Federal regulators have not said whether additional application windows will be offered, raising the stakes for companies trying to decide whether to act now or wait for more clarity.
For smaller operators, especially, the financial burden alone could be enough to keep them on the sidelines.
“The risks to applicants are almost entirely financial,” said Ghaith. “This registration cannot be used against your local or state licenses, nor can it be used to subject you to additional regulations in the state market.”
But that does not mean the cost is limited to the application itself.
“It is important to note that you may have additional unexpected expenses in order to actually benefit from your registration,” Ghaith said.
What It Means for Michigan
The development carries particular importance for Michigan, one of the largest cannabis markets in the United States.
But Michigan’s industry is overwhelmingly driven by recreational marijuana sales, while the federal registration process appears focused on medical cannabis operators—at least for now.
The gap is staggering: In March, Michigan medical marijuana sales totaled less than $500,000, compared to roughly $255 million in recreational sales.
That disconnect puts Michigan operators in a difficult position—forced to decide whether to invest in a shrinking segment of the market for a chance at a future one that doesn’t yet fully exist.
Companies with existing medical licenses may be better positioned to apply, while others may need to consider whether expanding into the medical side is worth the cost and complexity.
“Companies with existing medical licenses are essentially assured the opportunity to enter into the federal market, provided this registration does not impact their ability to operate in the state market,” said Ghaith.
Still, he emphasized that participation is not a requirement for survival—at least not yet.
“This should not be viewed as a ‘must’ for companies looking to maintain the status quo,” Ghaith said. “However, for operators interested in the potential federal market, this offers the opportunity to be first in line.”
What that future market looks like remains an open question.
“We still are unsure what the federal market actually looks like,” he said. “Is this going to be simply a federal research network? For now, yes—that is likely. The framework is based around research, which will likely open the door to pharmaceutical companies and federal government projects.”
That reality could force Michigan operators to rethink how they position themselves—not just for retail growth, but for credibility in a more regulated, research-driven environment.
“Operators taking the leap should look at gaining accreditation to help bolster their reputation and desirability in a research-based market,” Ghaith said. “This means pursuing certifications like GAP, GMP, or CSQ to legitimize their operations.”
At the same time, companies that secure early federal recognition could gain a critical advantage if interstate commerce eventually becomes a reality.
A Short Clock—and High-Stakes Decisions
With the application window now open, cannabis businesses across the country are weighing whether to act—or sit this one out.
For Michigan companies, the decision may come down to a stark calculation: invest now, with limited clarity, or risk being locked out of whatever comes next.
If federal policy continues evolving, those who move early could help shape the industry’s future.
Those who wait may find that future already taking shape—without them.
